DRUG ELUTING STENTS MARKET ANALYSIS

Drug Eluting Stents Market, By Product Type (Polymer-based Coatings, Polymer free Coatings (Micro porous Surface, Micro structured Surface, Slotted Tubular Surface, and Nanoporous Surface), By Application (Coronary Artery Disease, Peripheral Artery Disease, and Others), By End User (Hospitals, Cardiac Catheterization Labs, Ambulatory Surgical Centers, and Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Feb 2025
Code : CMI566
Pages :150
Formats :
Excel and PDF
Industry : Medical Devices

Drug Eluting Stents Market Size and Trends

The Global Drug Eluting Stents Market is estimated to be valued at USD 8.49 Bn in 2025 and is expected to reach USD 15.22 Bn by 2032 exhibiting a compound annual growth rate (CAGR) of 8.7% from 2025 to 2032.

Key Takeaways of the Drug Eluting Stents Market:

By product type, the polymer-based coatings segment is expected to contribute the highest share of the market with 52.6% in 2025.
By application, the coronary artery disease segment is expected to contribute the highest share of the market with 43.7% in 2025.
By end user, the hospitals segment is expected to contribute the highest share of the market with 40.8% in 2025.
North America is expected to top the global market with 35.8% share, followed by Asia Pacific with 28.2% share in 2025.

Market Overview:

The global drug eluting stents market is expected to witness a positive growth trend over the forecast period. Factors such as rising prevalence of cardiovascular diseases, growing geriatric population, rising healthcare expenditures, increasing adoption of minimally invasive surgeries and interventional cardiology are expected to drive the market growth during this period. Moreover, ongoing technological advancements in the field of drug eluting stents including bioresorbable stents and nano-technology coatings are further expected to provide new growth opportunities to market players in the coming years. However, factors such as stringent regulatory approval process and product recalls may hinder the market growth to some extent during the forecast period.